{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:20:01Z","timestamp":1787750401338,"version":"build-2784847793"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      <jats:bold>Background:<\/jats:bold>\n                      The diagnosis of high-grade dysplastic nevus (HGDNs) can present a challenge for a pathologist. The utility of combined AMBRA1 and loricrin staining for the diagnosis of HGDN was evaluated using preferentially expressed antigen in melanoma (PRAME) as a comparator.\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>Materials and methods:<\/jats:bold>\n                      A cohort of 145 cases of HGDN was selected from a consecutive series of 409 dysplastic nevi ascertained in a single pathology service between 2015 and 2019. Combined immunohistochemistry for AMBRA1 and loricrin expression in the epidermis overlying the HGDN was consensus scored by 2 experienced pathologists. PRAME immunohistochemistry was also consensus scored in the melanocyte population using a five-point scale (0\u20134+).\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>Results:<\/jats:bold>\n                      All HGDNs showed maintenance of either 1 or both AMBRA1 and loricrin epidermal expression with 3 exceptions. In 1 instance, a focus of melanocytes within the HGDN was associated with loss of both markers in the overlying epidermis and the melanocytes in the focus were strongly positive (4+) for PRAME. On expert review, the diagnosis was changed to thin melanoma. In the other 2 cases showing loss of both markers, the absence of staining was focal and restricted to mounds of parakeratosis. Most HGDN were negative for PRAME although 48% were positive to some degree and 4% showed a 4+ expression.\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>Observations:<\/jats:bold>\n                      Clinical follow-up showed no evidence of progression or metastasis. We found that 23 patients (16%) had previous, concurrent, or subsequent early stage melanomas and 2 patients (1%) had previous melanoma in situ. One HGDN recurred after 3 years, and the further excision sample showed recurrent HGDN only.\n                    <\/jats:p>\n                    <jats:p>We observed that mild epidermal hyperplasia and parakeratosis were often found in HGDNs, suggesting an active melanocyte\u2013epidermal interaction in the lesions. We speculate that epidermal hyperplasia resulted in some of the HGDN showing single-cell loricrin gaps or thinning of the loricrin band. AMBRA1, loricrin, and PRAME staining was additionally performed on 39 benign melanocytic nevi covering a range of types for comparison. Epidermal hyperplasia was generally not seen and almost all cases showed maintenance of both epidermal AMBRA1 and loricrin, with loricrin gaps and thinning seen only in 3 Meyerson nevi where there was parakeratosis (3\/5 Meyerson nevi).<\/jats:p>\n                    <jats:p>\n                      <jats:bold>Conclusion:<\/jats:bold>\n                      This study suggests that AMBRA1 and loricrin staining is a useful biomarker to confirm the diagnosis and\/or to signal low-risk behavior in HGDN, particularly in cases where 4+ PRAME staining could potentially point to a melanoma diagnosis.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/dad.0000000000003330","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T07:00:13Z","timestamp":1782457213000},"page":"691-697","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Utility of Combined Immunohistochemical Staining for AMBRA1 and Loricrin for Improving the Pathologic Diagnosis of High-Grade Dysplastic Nevi"],"prefix":"10.1097","volume":"48","author":[{"given":"Philip","family":"Sloan","sequence":"first","affiliation":[{"name":"Translation and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, United Kingdom;"},{"name":"Cellular Pathology, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhtar","family":"Husain","sequence":"additional","affiliation":[{"name":"Translation and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Lye","sequence":"additional","affiliation":[{"name":"Cellular Pathology, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Best","sequence":"additional","affiliation":[{"name":"Translation and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Walker","sequence":"additional","affiliation":[{"name":"Translation and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Richardson","sequence":"additional","affiliation":[{"name":"Translation and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Armstrong","sequence":"additional","affiliation":[{"name":"John Dawson Drug Discovery and Development Research Institute, University of Sunderland, Sunderland, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny","family":"Lovat","sequence":"additional","affiliation":[{"name":"Translation and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"R1-20260819","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/archderm.1978.01640170032006","article-title":"Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome","volume":"114","author":"Clark","year":"1978","journal-title":"Arch Dermatol"},{"key":"R2-20260819","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/dermatopathology12010003","article-title":"Dysplastic nevi and superficial borderline atypical melanocytic lesions: description of an algorithmic clinico-pathological classification","volume":"12","author":"Menzinger","year":"2025","journal-title":"Dermatopathology (Basel)"},{"key":"R4-20260819","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.clindermatol.2024.09.007","article-title":"MPATH-Dx version 2.0 schema for melanocytic lesions: a robust tool for standardized diagnostic reporting","volume":"43","author":"Barnhill","year":"2025","journal-title":"Clin Dermatol"},{"key":"R5-20260819","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/DAD.0000000000002847","article-title":"Utilizing PRAME expression and a meta-analytic framework for iSALT to explore atypical late-onset nevi of the elderly and their relationship with lentiginous and nested nevoid melanomas","volume":"46","author":"Kossard","year":"2024","journal-title":"Am J Dermatopathol"},{"key":"R6-20260819","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/DAD.0000000000002584","article-title":"Pitfalls of PRAME immunohistochemistry in a large series of melanocytic and nonmelanocytic lesions with literature review","volume":"46","author":"Turner","year":"2024","journal-title":"Am J Dermatopathol"},{"key":"R7-20260819","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/DAD.0000000000002932","article-title":"Clinicopathologic features of PRAME-positive common melanocytic nevi: a case-control study","volume":"47","author":"Knittel","year":"2025","journal-title":"Am J Dermatopathol"},{"key":"R8-20260819","first-page":"156","article-title":"Epidermal autophagy and beclin 1 regulator 1 and loricrin: a paradigm shift in the prognostication and stratification of the American joint committee on cancer stage I melanomas","volume":"182","author":"Ellis","year":"2020","journal-title":"Br J Dermatol"},{"key":"R9-20260819","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/bjd\/ljad459","article-title":"Validation of epidermal AMBRA1 and loricrin (AMBLor) as a prognostic biomarker for nonulcerated American joint committee on cancer stage I\/II cutaneous melanoma","volume":"190","author":"Ewen","year":"2024","journal-title":"Br J Dermatol"},{"key":"R10-20260819","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/cup.14744","article-title":"Grading melanocytic dysplasia: updated histopathologic criteria","volume":"53","author":"Shea","year":"2026","journal-title":"J Cutan Pathol"},{"key":"R11-20260819","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1097\/PAS.0000000000001134","article-title":"PRAME expression in melanocytic tumors","volume":"42","author":"Lezcano","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"R12-20260819","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/DAD.0000000000002440","article-title":"Immunohistochemistry for PRAME in dermatopathology","volume":"45","author":"Lezcano","year":"2023","journal-title":"Am J Dermatopathol"},{"key":"R13-20260819","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.3390\/cancers13153864","article-title":"Diffuse PRAME expression is highly specific for thin melanomas in the distinction from severely dysplastic nevi but does not distinguish metastasizing from non-metastasizing thin melanomas","volume":"13","author":"Gassenmaier","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R14-20260819","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1097\/DAD.0000000000003104","article-title":"PRAME expression in recurrent\/persistent melanocytic nevi","volume":"47","author":"Kucharik","year":"2025","journal-title":"Am J Dermatopathol"},{"key":"R15-20260819","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1001\/jamadermatol.2023.6417","article-title":"Immunohistochemistry for diagnosing melanoma in older adults","volume":"160","author":"Ojukwu","year":"2024","journal-title":"JAMA Dermatol"},{"key":"R16-20260819","doi-asserted-by":"crossref","first-page":"10095","DOI":"10.1038\/s41467-025-65051-0","article-title":"Multimodal AI and tumour microenvironment integration predicts metastasis in cutaneous melanoma","volume":"16","author":"Andrew","year":"2025","journal-title":"Nat Commun"},{"key":"R17-20260819","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jaad.2025.01.013","article-title":"Development of a treatment decision aid for patients with dysplastic nevi who are candidates for re-excision","volume":"92","author":"Roland-McGowan","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"R18-20260819","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s13671-025-00476-w","article-title":"Do all dysplastic nevi need re-excision?","volume":"14","author":"Miles","year":"2025","journal-title":"Curr Dermatol Rep"}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/DAD.0000000000003330","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:32:53Z","timestamp":1787747573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/DAD.0000000000003330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000003330","relation":{},"ISSN":["0193-1091","1533-0311"],"issn-type":[{"value":"0193-1091","type":"print"},{"value":"1533-0311","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]}}}